Literature DB >> 3257515

Immunostimulatory capabilities of highly enriched Langerhans cells in vitro.

C A Picut1, C S Lee, E P Dougherty, K L Anderson, R M Lewis.   

Abstract

Langerhans cells (LC) are epidermal antigen-presenting cells capable of inducing allogenic, antigen-specific, and cytotoxic T cell proliferation. Previous studies have examined the dynamics of LC maintained in vitro in crude epidermal cell (EC) suspensions in which the major cell type is the keratinocyte (KC). To avoid the confounding effects of KC and other immunoregulatory cells on LC dynamics in vitro, highly enriched murine LC (85%) were studied, through 72 h of incubation in vitro, for their ability to present alloantigen (in a primary allogenic proliferation assay) and foreign antigen (in a secondary autologous proliferation assay). The results were compared to similar studies using crude EC suspensions. Freshly prepared LC are very poor stimulators of a primary allogenic proliferation response, with a 12- to 16-fold increase in stimulatory capacity by 72 h using panned-enriched and crude EC suspensions, respectively. Similarly, freshly prepared LC are weak stimulators of a secondary autologous proliferation response, with a 2.5- to 6-fold increase in immunostimulatory capability by 72 h. The overall increased stimulatory effect observed with the crude EC suspensions compared to highly enriched LC is most likely attributed to the effect of KC on T cell proliferation, rather than to a maturation effect of KC on LC during the 72 h of in vitro incubation. Using back-scattered electron imaging, the surface density of MHC-class II molecules (Ia) increased three- to fourfold through culture, which parallels the increase in functional ability. This study demonstrates that LC in either a crude or highly enriched cell suspension mature into potent immunostimulatory cells after incubation in vitro with an increased surface expression of Ia molecules. Keratinocytes are not necessary for LC maturation in vitro, but seem to exert some stimulatory effect by enhancing lymphocyte proliferation in the functional assay system.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3257515     DOI: 10.1111/1523-1747.ep12462221

Source DB:  PubMed          Journal:  J Invest Dermatol        ISSN: 0022-202X            Impact factor:   8.551


  7 in total

Review 1.  Dynamic nature and function of epidermal Langerhans cells in vivo and in vitro: a review, with emphasis on human Langerhans cells.

Authors:  M B Teunissen
Journal:  Histochem J       Date:  1992-10

2.  Antigen-bearing dendritic cells in the draining lymph nodes of contact sensitized mice: cluster formation with lymphocytes.

Authors:  M Cumberbatch; I Illingworth; I Kimber
Journal:  Immunology       Date:  1991-09       Impact factor: 7.397

3.  In vitro primary sensitization and restimulation of hapten-specific T cells by fresh and cultured human epidermal Langerhans' cells.

Authors:  C Moulon; J Péguet-Navarro; P Courtellemont; G Redziniak; D Schmitt
Journal:  Immunology       Date:  1993-11       Impact factor: 7.397

4.  Antigenic competition in contact sensitivity. Evidence for changes in dendritic cell migration and antigen handling.

Authors:  I Kimber; S Hill; J A Mitchell; S W Peters; S C Knight
Journal:  Immunology       Date:  1990-10       Impact factor: 7.397

5.  MHC class II expression by Langerhans' cells and lymph node dendritic cells: possible evidence for maturation of Langerhans' cells following contact sensitization.

Authors:  M Cumberbatch; S J Gould; S W Peters; I Kimber
Journal:  Immunology       Date:  1991-11       Impact factor: 7.397

6.  Phenotypic characteristics of antigen-bearing cells in the draining lymph nodes of contact sensitized mice.

Authors:  M Cumberbatch; I Kimber
Journal:  Immunology       Date:  1990-11       Impact factor: 7.397

7.  Milestones in the research on skin epidermal Langerhans/dendritic cells (LCs/DCs) from the discovery of Paul Langerhans 1868-1989.

Authors:  Yechiel Becker
Journal:  Virus Genes       Date:  2003       Impact factor: 2.198

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.